Currently going for $4.37 apiece, Wall Street is pounding the table on this healthcare name.On August 31, the company announced that Mycapssa, the first and only oral somatostatin analog (SSA) approved as a long-term maintenance treatment for acromegaly patients who have responded to and tolerated octreotide or lanreotide (other approved therapies), had been launched one month ahead of guidance. He called bottom of stocks in '09, and recommended AMZN before it soared an extraordinary 1,800%.
Bright Spots The 23% YOY growth of Tilray’s recreational sales was a positive development.
Overall revenue for the period was $50.4 million, down 3.2% quarter-over-quarter. By creating an account, you agree to theTerms of Service and acknowledge our Privacy Policy. Catch financial instability early by keeping an eye out for these red flags from your partner. Buy) along with a $17 price target. Acromegaly is an orphan disease typically caused by a benign tumor on the pituitary that results in the excessive secretion of growth hormones, causing bone overgrowth and enlargement of internal organs with co-morbidities.In terms of pricing, a 28-day supply goes for $5,152, with CHMA intending to build on physician and patient experience with octreotide, incorporate telemedicine and build a sales team of 45 representatives.Weighing in on this development for Piper Sandler, 5-star analyst Edward Tenthoff tells clients he is optimistic about the therapy’s prospects. Tilray revenue hit by lower recreational, medical cannabis sales.
Tilray is seeing solid but not spectacular growth in the recreational sector. The company’s total cannabis kilogram equivalents sold rose by 92.4% YOY to 5,794 kilograms. (To watch Schwartz’s track record, click here)What does the rest of the Street have to say? Total cannabis sales in the consumer market were C$29.6 million ($21.99 million) in the third quarter, versus C$21.6 million ($16.05 million) in the second quarter.
Canada has become the first industrialized nation to legalize recreational use of cannabis, in an effort to keep pot out of the hands of underage users and defeat the black market.
He continues to put an Overweight rating and $19 price target on the stock, implying 319% upside potential. “With the banning of Huawei CEVA’s customer, ZTE, is getting more of the 5G infrastructure business in China and we expect this revenue to increase from $1M in Q2 to $2M to $2.5M in Q3. Canada’s decision to double the number of stores that sell cannabis should boost Tilray’s sales.
5G, first introduced two years ago, is expanding past its initial phases and has reached the edge of a great boom. "Our growth internationally and in Canada continue to be limited by lack of supply that we expect to improve over time," Tilray Chief Financial Officer Mark Castaneda said on a conference call with analysts. The 23% YOY growth of Tilray’s recreational sales was a positive development. Adult-use cannabis sales in Canada fell 15% to $17.6 million.